search
Back to results

Multimodal Prehabilitation for Lung Cancer Surgery (MMP-LUNG)

Primary Purpose

Lung Cancer, Surgery

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Mixed-nutriend supplement (NUT)
Multimodal Prehabilitation (MM)
Placebo Control (CTRL)
Sponsored by
Stéphanie Chevalier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Lung Cancer focused on measuring Prehabilitation, Nutritional Supplement

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adults aged 45 years and over Diagnosed with NSCLC stages I, II or IIIa and scheduled for video-assisted thoracic surgery (VATS) or open thoracotomy surgery for cancer resection At nutritional risk (defined as Patient Generated-Subjective Global Assessment score = or >3) Exclusion Criteria: Prior recent (<2 months) adjuvant therapy (chemo- or radio-therapy) Inability to perform, or comorbidities contraindicating, exercise (defined as CPET <10 mL O2/kg/min) Unable to walk (uses a wheelchair) Allergy to milk or seafood Hypercalcemia (total serum Ca >2.60 mmol/L or ionized Ca >1.30 mmol/L) Hypervitaminosis D (serum 25(OH)D >375 nmol/L) Glomerular filtration rate (<30 mL/min/1.73m2) Insufficient understanding of English or French to provide informed consent Patients taking omega-3 FA supplements will be asked to withhold them during the study; those taking vitamin D will continue unless baseline serum 25(OH)D >80 nmol/L.

Sites / Locations

  • Research Institute of the McGill University Health CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Arm Label

Control (CTRL)

Mixed-nutriend supplement (NUT)

Multi-modal intervention (MM)

Arm Description

Participants will be treated following Enhanced Recovery After Surgery (ERAS) protocols + placebo supplements containing maltodextrin and sunflower oil

Mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids

Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization with dietician, NUT intervention, and relaxation strategies.

Outcomes

Primary Outcome Measures

Change in preoperative functional walking capacity
6-Minute walking test (6MWT): measured as the distance walked during 6 minutes, along a 20-m corridor, expressed in meters
Postoperative functional walking capacity
6-Minute walking test (6MWT): measured as the distance walked during 6 minutes, along a 20-m corridor, expressed in meters

Secondary Outcome Measures

Change in handgrip strength
Handgrip strength using hand-held Jamar dynamometer, measured in kg
Change in total skeletal muscle mass
Estimated using deuterium-labeled creatine (D3-creatine), measured in kg
Change in foreleg muscle surface area
Skeletal muscle surface area will be measured in the dominant foreleg, using peripheral quantitative computerized tomography (pQCT, Stratec XCT2000), measured in cm2.
Change in foreleg myosteatosis (radiodensity)
Skeletal muscle radiodensity will be measured in the dominant foreleg, using peripheral quantitative computerized tomography (pQCT, Stratec XCT2000), measured in mg/cm3.
Change in body weight and composition
Soft lean and fat mass measured by bioelectrical impedance (seca mBCA 515)
Change in self-reported quality of life
Measured by the 36-item Short Form Survey (SF36, score 0-100; higher means better quality of life)
Change in self-reported functional assessment
Measured by the Functional Assessment of Cancer Therapy - Lung questionnaire (FACT-L score 0-136, higher means better quality of life)
Length of hospital stay
Recorded from medical charts, expressed in days
Number and severity of postoperative complications
Recorded from medical charts and graded by severity following the Clavien-Dindo classification

Full Information

First Posted
June 22, 2023
Last Updated
July 12, 2023
Sponsor
Stéphanie Chevalier
Collaborators
Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT05955248
Brief Title
Multimodal Prehabilitation for Lung Cancer Surgery
Acronym
MMP-LUNG
Official Title
A Novel Multimodal Intervention for Surgical Prehabilitation of Patients With Lung Cancer: the MMP-LUNG Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 26, 2023 (Actual)
Primary Completion Date
September 20, 2025 (Anticipated)
Study Completion Date
March 20, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Stéphanie Chevalier
Collaborators
Canadian Institutes of Health Research (CIHR)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of this randomized controlled trial (RCT) is to investigate whether a multimodal prehabilitation intervention combining a mixed-nutrient supplement with structured exercise training (MM) or the supplement alone (NUT), against a placebo (CTRL), leads to improvement in functional capacity and postoperative outcomes in surgical patients with lung cancer, at nutritional risk. This will be tested in a single centre RCT of 3 parallel arms, double-blinded for the supplement. Female and male participants (n=168, >=45 y) will be randomized to a 10-week intervention spanning 4 weeks pre-surgery and 6 weeks post-hospital discharge. The primary outcome is functional capacity as measured by the 6-minute walk test. Secondary outcomes include muscle mass, quality and strength, quality of life, length of hospital stay, and postoperative complications.
Detailed Description
RATIONALE: The preoperative period is an opportune time to actively engage and empower patients in improving their functional, nutritional and mental status in anticipation of the surgical stress. Considering that lung cancer patients often present with poor nutritional status and physical function prior to surgery, providing a nutritional supplement to increase protein, leucine, vitamin D and omega-3 fatty acid FA intake with a structured exercise program and relaxation techniques should improve muscle mass, strength and physical performance. MAIN OBJECTIVE: to test the effect of a multimodal RCT prehabilitation intervention (MM) combining a mixed-nutrient supplement with structured exercise training or the supplement alone (NUT) against a placebo (CTRL), on functional pre- and postoperative outcomes in surgical patients with lung cancer at nutritional risk. STUDY DESIGN: 10-week randomized controlled trial of 3 parallel arms, double-blinded for supplement: control (CTRL), multi-nutrient supplement (NUT) and multimodal intervention (MM). After baseline assessment, patients will be randomized to either group in a 1:1:1 CTRL:NUT:MM ratio using a computer-generated randomization scheme by permuted block sizes, with stratification by sex and functional capacity (< or > 450 m on the 6-minute walk test (6MWT). Consecutive adult patients = or > 45 years scheduled for elective video-assisted thoracic surgery or open thoracotomy surgery of non-small cell lung cancer (NSCLC) stages I, II or IIIa and a Patient-Generated Subjective Global Assessment (PG-SGA) score = or > 3, will be approached following their first appointment with their surgeon at the McGill University Health Centre (MUHC)-Montreal General Hospital. INTERVENTION: The NUT arm will ingest a multi-nutrient supplement consisting of whey protein + leucine + viatmin D, and fish oil. The CTRL participants will receive placebo supplements with the same physical aspect, flavor and packaging as the active supplement.The MM arm will receive the NUT intervention in addition to performing structured exercise and relaxation techniques for 4 weeks prior to surgery and 6 weeks after hospital discharge. OUTCOMES: Primary: physical capacity measured by the 6MWT; Secondary: physical function, muscle strength, total skeletal muscle mass, leg muscle volume and density, body composition, quality of life, length of stay and post-operative complications; Other: dietary intake, physical activity, exercise tolerance, pulmonary function, clinical markers. STATISTICAL ANALYSIS: Intention-to-treat analysis will be performed in the primary analyses. For preoperative data, analysis of covariance (ANCOVA) will compare between-group differences at 4-week preoperative time, conditioned for baseline data, including predefined covariates in the model (age, sex, BMI). The hypothesis of full recovery from the intervention at 6 weeks postoperative (i.e. 6MWT returning back to or exceeding baseline) will be tested by logistic regression (yes/no). Between-group changes in other outcomes will be evaluated as differences in mean or proportions, as appropriate, with 95% CIs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Surgery
Keywords
Prehabilitation, Nutritional Supplement

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial, 3 parallel arms (multimodal intervention, MM; nutritional supplement, NUT; control, CTRL), double-blind and placebo-controlled for supplement, single centre.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The blinding of exercise is not possible therefore participants will be aware if they are in the MM group. However, research personnel performing outcome assessments will be blinded to group allocation. Groups CTRL and NUT will be double-blinded. Supplements will be packaged by the supplier in coded-labeled sachets (for powder) and bottles (for oil). The supplier will disclose the code to a research person not associated with the trial. Research staff will prepare boxes of supplements (or placebo) according to coded group allocation. All participants will be instructed to not self-supplement with commercially available products, to minimize the risk of group contamination. All data and biological samples will be coded such that participant's identification will not be disclosed to research personnel conducting analyses.
Allocation
Randomized
Enrollment
168 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control (CTRL)
Arm Type
Placebo Comparator
Arm Description
Participants will be treated following Enhanced Recovery After Surgery (ERAS) protocols + placebo supplements containing maltodextrin and sunflower oil
Arm Title
Mixed-nutriend supplement (NUT)
Arm Type
Active Comparator
Arm Description
Mixed nutrient supplement containing whey protein, leucine, vitamin D and omega 3 fatty acids
Arm Title
Multi-modal intervention (MM)
Arm Type
Active Comparator
Arm Description
Multimodal prehabilitation including structured exercise (1 supervised exercise session per week + home-based exercise program), nutritional optimization with dietician, NUT intervention, and relaxation strategies.
Intervention Type
Dietary Supplement
Intervention Name(s)
Mixed-nutriend supplement (NUT)
Intervention Description
Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the active multi-nutrient supplement made of whey protein + leucine + vitamin D doses pre-mixed in unlabeled packets prepared by Gruppo Nutrition to dilute in a cup (250 mL) of water. In addition, participants will ingest 15 mL of fruit-flavored fish oil, provided as a liquid oil. They will receive a dosing cup, pre-marked to 15 mL, for a total dose providing 2120 mg eicosapentaenoic acid (EPA) and 1320 mg docosahexaenoic acid (DHA).
Intervention Type
Other
Intervention Name(s)
Multimodal Prehabilitation (MM)
Intervention Description
Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive the NUT intervention + structured exercise training prescribed by a kinesiologist (1. 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2. 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps). Training will be performed for 4 weeks prior to surgery (1x/week supervised by kinesiologist at hospital, 2x/week at alone at home)
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Control (CTRL)
Intervention Description
Participants will follow ERAS protocol and will receive dietary counselling and anxiety management counselling as needed. They will receive a placebo dietary supplement made of maltodextrin and sunflower oil.
Primary Outcome Measure Information:
Title
Change in preoperative functional walking capacity
Description
6-Minute walking test (6MWT): measured as the distance walked during 6 minutes, along a 20-m corridor, expressed in meters
Time Frame
From baseline (4 weeks pre-surgery) to surgery
Title
Postoperative functional walking capacity
Description
6-Minute walking test (6MWT): measured as the distance walked during 6 minutes, along a 20-m corridor, expressed in meters
Time Frame
6 weeks after surgery
Secondary Outcome Measure Information:
Title
Change in handgrip strength
Description
Handgrip strength using hand-held Jamar dynamometer, measured in kg
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in total skeletal muscle mass
Description
Estimated using deuterium-labeled creatine (D3-creatine), measured in kg
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in foreleg muscle surface area
Description
Skeletal muscle surface area will be measured in the dominant foreleg, using peripheral quantitative computerized tomography (pQCT, Stratec XCT2000), measured in cm2.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in foreleg myosteatosis (radiodensity)
Description
Skeletal muscle radiodensity will be measured in the dominant foreleg, using peripheral quantitative computerized tomography (pQCT, Stratec XCT2000), measured in mg/cm3.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in body weight and composition
Description
Soft lean and fat mass measured by bioelectrical impedance (seca mBCA 515)
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in self-reported quality of life
Description
Measured by the 36-item Short Form Survey (SF36, score 0-100; higher means better quality of life)
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in self-reported functional assessment
Description
Measured by the Functional Assessment of Cancer Therapy - Lung questionnaire (FACT-L score 0-136, higher means better quality of life)
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Length of hospital stay
Description
Recorded from medical charts, expressed in days
Time Frame
6 weeks after surgery
Title
Number and severity of postoperative complications
Description
Recorded from medical charts and graded by severity following the Clavien-Dindo classification
Time Frame
6 weeks after surgery
Other Pre-specified Outcome Measures:
Title
Change in dietary intake
Description
Collected from 3-day food diaries, using a mobile application (Keenoa)
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in plasma phospholipid fatty acid profile
Description
Plasma lipids will be extracted with organic solvents, phospholipids isolated on thin-layer chromatography, and FAs methylated for determination by gas chromatography-flame-ionization analysis. Change in long-chain omega-3 fatty acids will be used as an objective measure of adherence to fish oil supplement.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in serum vitamin D 25(OH)D concentrations
Description
Concentrations will be measured by the MUHC-Central Lab. Used as an objective measure of adherence to the supplement.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in serum C-Reactive Protein (CRP)
Description
Measured as high-sensitive CRP by the MUHC-Central Lab.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in serum albumin
Description
Analyzed by standard procedures at the MUHC-Central Lab
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in serum pre-albumin
Description
Analyzed by standard procedures at the MUHC-Central Lab
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in serum hemoglobin
Description
Analyzed by standard procedures at the MUHC-Central Lab
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in complete blood count
Description
Analyzed by standard procedures at the MUHC-Central Lab
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in preoperative exercise tolerance
Description
Assessed as oxygen consumption during cardiopulmonary exercise testing (CPET) at anaerobic threshold and peak exercise, in mL O2/kg/min
Time Frame
From baseline (4 weeks pre-surgery) to surgery
Title
Change in forced expiratory volume (FEV1)
Description
Spirometry standard methods to measure the forced expiratory volume (FEV1)
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in forced vital capacity (FVC)
Description
Spirometry standard methods to measure the forced vital capacity (FVC) and calculate FEV1/FVC ratio.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in self-reported physical activity level score
Description
Measured with the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire, score 0 - x (no maximum score), higher mean more activity.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in physical activity
Description
Measured by accelerometry (Actigraph wGT3X-BT) during the intervention. Step count and time spent at sedentary, light, moderate/ vigorous activity, and sleeping time will be recorded.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in anxiety/depression score
Description
Hospital Anxiety and Depression Scale (questionnaire). Scoring for each item ranges from zero to three. A subscale score >8 denotes anxiety or depression.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Change in Patient-Generated Subjective Global Assessment (PG-SGA) score
Description
PG-SGA questionnaire, total score. A higher score indicates higher nutritional risk or malnutrition.
Time Frame
From baseline (4 weeks pre-surgery) to 6 weeks after surgery
Title
Number of adverse events
Description
Any adverse event, related or not to the intervention
Time Frame
Through study completion, an average of 10 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults aged 45 years and over Diagnosed with NSCLC stages I, II or IIIa and scheduled for video-assisted thoracic surgery (VATS) or open thoracotomy surgery for cancer resection At nutritional risk (defined as Patient Generated-Subjective Global Assessment score = or >3) Exclusion Criteria: Prior recent (<2 months) adjuvant therapy (chemo- or radio-therapy) Inability to perform, or comorbidities contraindicating, exercise (defined as CPET <10 mL O2/kg/min) Unable to walk (uses a wheelchair) Allergy to milk or seafood Hypercalcemia (total serum Ca >2.60 mmol/L or ionized Ca >1.30 mmol/L) Hypervitaminosis D (serum 25(OH)D >375 nmol/L) Glomerular filtration rate (<30 mL/min/1.73m2) Insufficient understanding of English or French to provide informed consent Patients taking omega-3 FA supplements will be asked to withhold them during the study; those taking vitamin D will continue unless baseline serum 25(OH)D >80 nmol/L.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stéphanie Chevalier, PhD
Phone
(514) 934-1934
Ext
35019
Email
stephanie.chevalier@mcgill.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stéphanie Chevalier, PhD
Organizational Affiliation
McGill University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Institute of the McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphanie Chevalier, PhD
Phone
(514) 934-1934
Ext
35019
Email
stephanie.chevalier@mcgill.ca

12. IPD Sharing Statement

Learn more about this trial

Multimodal Prehabilitation for Lung Cancer Surgery

We'll reach out to this number within 24 hrs